Table 1.
Behavioral effects of chronic citalopram administration
| Tail suspension test
|
Elevated plus maze
|
Light-dark box
|
||||||
|---|---|---|---|---|---|---|---|---|
| Time immobile (sec) | Immobility latency (sec) | Open arm time (sec) | Open arm entries (no.) | Total entries (no.) | Total distance (m) | Transitions (no.) | Light side time (sec) | |
| Male | ||||||||
| WT male VEH | 95.8 ± 12.4 | 62.9 ± 13.9 | 33.6 ± 10.9 | 5.2 ± 1.3 | 17.8 ± 1.4 | 7.4 ± 0.5 | 18.1 ± 3.2 | 116.2 ± 21.8 |
| WT male CIT | 91.1 ± 9.9 | 62.8 ± 8.3 | 42.5 ± 9.3 | 4.4 ± 1.3 | 20.8 ± 2.3 | 6.0 ± 1.2 | 13.4 ± 2.7 | 231.0 ± 36.0 |
| R2KO male VEH | 132.8 ± 17.2 | 47.5 ± 5.4 | 31.2 ± 8.56 | 5.2 ± 1.2 | 19.2 ± 2.4 | 6.2 ± 0.6 | 14.2 ± 1.6 | 109.9 ± 18.3 |
| R2KO male CIT | 112.4 ± 12.4 | 58.9 ± 9.0 | 42.4 ± 11.4 | 4.5 ± 0.7 | 23.4 ± 3.1 | 5.9 ± 0.7 | 11.8 ± 1.2 | 109.4 ± 13.4 |
| Female | ||||||||
| WT female VEH | 118.8 ± 20.8 | 61.4 ± 9.8 | 46.0 ± 12.8 | 5.1 ± 1.1 | 16.3 ± 1.7 | 5.6 ± 0.8 | 8.9 ± 2.8 | 152.5 ± 60.7 |
| WT female CIT | 144.7 ± 11.1 | 36.4 ± 4.8 | 38.9 ± 12.0 | 6.3 ± 1.7 | 12.9 ± 1.3 | 6.2 ± 0.9 | 11.1 ± 1.9 | 107.5 ± 22.0 |
| R2KO female VEH | 136.6 ± 9.4 | 42.4 ± 3.8 | 13.1 ± 6.2 | 2.7 ± 1.0 | 17.8 ± 1.6 | 4.7 ± 0.6 | 8.2 ± 2.4 | 77.8 ± 33.3 |
| R2KO female CIT | 135.4 ± 11.4 | 50.7 ± 6.0 | 41.0 ± 17.2 | 4.0 ± 1.0 | 13.0 ± 2.2 | 5.3 ± 0.6 | 6.9 ± 1.4 | 145.5 ± 46.4 |
CIT, Citalopram; VEH, vehicle.